BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 36794675)

  • 1. Receptor-binding domain-based SARS-CoV-2 vaccine adjuvanted with cyclic di-adenosine monophosphate enhances humoral and cellular immunity in mice.
    Germanó MJ; Giai C; Cargnelutti DE; Colombo MI; Blanco S; Konigheim B; Spinsanti L; Aguilar J; Gallego S; Valdez HA; Mackern-Oberti JP; Sanchez MV
    J Med Virol; 2023 Feb; 95(2):e28584. PubMed ID: 36794675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity.
    Ghaemi A; Roshani Asl P; Zargaran H; Ahmadi D; Hashimi AA; Abdolalipour E; Bathaeian S; Miri SM
    Front Immunol; 2022; 13():974364. PubMed ID: 36159845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safe plant Hsp90 adjuvants elicit an effective immune response against SARS-CoV2-derived RBD antigen.
    Ramos-Duarte VA; Orlowski A; Jaquenod de Giusti C; Corigliano MG; Legarralde A; Mendoza-Morales LF; Atela A; Sánchez MA; Sander VA; Angel SO; Clemente M
    Vaccine; 2024 May; 42(14):3355-3364. PubMed ID: 38631949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine.
    Li CJ; Jiang CL; Chao TL; Lin SY; Tsai YM; Chao CS; Su YT; Chen CJ; Chang SY; Lin FJ; Chang SC
    Appl Microbiol Biotechnol; 2023 May; 107(9):2983-2995. PubMed ID: 36988669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hybrid response to SARS-CoV-2 and
    Portilho AI; Hermes Monteiro da Costa H; Grando Guereschi M; Prudencio CR; De Gaspari E
    Hum Vaccin Immunother; 2024 Dec; 20(1):2346963. PubMed ID: 38745461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHO-produced RBD-Fc subunit vaccines with alternative adjuvants generate immune responses against SARS-CoV-2.
    Laotee S; Duangkaew M; Jivapetthai A; Tharakhet K; Kaewpang P; Prompetchara E; Phumiamorn S; Sapsutthipas S; Trisiriwanich S; Somsaard T; Roytrakul S; Duangkhae P; Ongpipattanakul B; Limpikirati P; Pornputtapong N; Arunmanee W
    PLoS One; 2023; 18(7):e0288486. PubMed ID: 37450510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein Vaccine.
    Liu D; An C; Bai Y; Li K; Liu J; Wang Q; He Q; Song Z; Zhang J; Song L; Cui B; Mao Q; Jiang W; Liang Z
    Viruses; 2022 Aug; 14(9):. PubMed ID: 36146661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TLR9 and STING agonists cooperatively boost the immune response to SARS-CoV-2 RBD vaccine through an increased germinal center B cell response and reshaped T helper responses.
    Yang JX; Tseng JC; Tien CF; Lee CY; Liu YL; Lin JJ; Tsai PJ; Liao HC; Liu SJ; Su YW; Hsu LC; Chen JK; Huang MH; Yu GY; Chuang TH
    Int J Biol Sci; 2023; 19(9):2897-2913. PubMed ID: 37324951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
    Arunachalam PS; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Röltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Spencer S; Doyle-Meyers L; Bohm RP; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O'Hagan DT; Van Der Most R; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar MS; King NP; Veesler D; Pulendran B
    Nature; 2021 Jun; 594(7862):253-258. PubMed ID: 33873199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A vaccine delivery system promotes strong immune responses against SARS-CoV-2 variants.
    Lei Z; Zhu L; Pan P; Ruan Z; Gu Y; Xia X; Wang S; Ge W; Yao Y; Luo F; Xiao H; Guo J; Ding Q; Yin Z; Li Y; Luo Z; Zhang Q; Chen X; Wu J
    J Med Virol; 2023 Feb; 95(2):e28475. PubMed ID: 36606607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus.
    Brzuska G; Zimna M; Baranska K; Szewczyk B; Strakova P; Ruzek D; Krol E
    Microbiol Spectr; 2023 Jun; 11(3):e0256422. PubMed ID: 37199661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates.
    Pino M; Abid T; Pereira Ribeiro S; Edara VV; Floyd K; Smith JC; Latif MB; Pacheco-Sanchez G; Dutta D; Wang S; Gumber S; Kirejczyk S; Cohen J; Stammen RL; Jean SM; Wood JS; Connor-Stroud F; Pollet J; Chen WH; Wei J; Zhan B; Lee J; Liu Z; Strych U; Shenvi N; Easley K; Weiskopf D; Sette A; Pollara J; Mielke D; Gao H; Eisel N; LaBranche CC; Shen X; Ferrari G; Tomaras GD; Montefiori DC; Sekaly RP; Vanderford TH; Tomai MA; Fox CB; Suthar MS; Kozlowski PA; Hotez PJ; Paiardini M; Bottazzi ME; Kasturi SP
    Sci Immunol; 2021 Jul; 6(61):. PubMed ID: 34266981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen.
    Wang Y; Wang L; Cao H; Liu C
    J Med Virol; 2021 Feb; 93(2):892-898. PubMed ID: 32691875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine based on folded receptor binding domain-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants.
    Gattinger P; Kratzer B; Tulaeva I; Niespodziana K; Ohradanova-Repic A; Gebetsberger L; Borochova K; Garner-Spitzer E; Trapin D; Hofer G; Keller W; Baumgartner I; Tancevski I; Khaitov M; Karaulov A; Stockinger H; Wiedermann U; Pickl WF; Valenta R
    Allergy; 2022 Aug; 77(8):2431-2445. PubMed ID: 35357709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Targeted RIG-I Receptor 5'Triphosphate Double Strain RNA-Based Adjuvant Significantly Improves the Immunogenicity of the SARS-CoV-2 Delta-Omicron Chimeric RBD-Dimer Recombinant Protein Vaccine.
    Bai Y; An C; Zhang X; Li K; Cheng F; Cui B; Song Z; Liu D; Zhang J; He Q; Liu J; Mao Q; Liang Z
    Viruses; 2023 Apr; 15(5):. PubMed ID: 37243185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of SARS-CoV-2 Trimeric Spike Protein Associated to Poly(I:C) Plus Alum.
    Dos-Santos JS; Firmino-Cruz L; da Fonseca-Martins AM; Oliveira-Maciel D; Perez GG; Roncaglia-Pereira VA; Dumard CH; Guedes-da-Silva FH; Santos ACV; Leandro MDS; Ferreira JRM; Guimarães-Pinto K; Conde L; Rodrigues DAS; Silva MVM; Alvim RGF; Lima TM; Marsili FF; Abreu DPB; Ferreira OC; Mohana Borges RDS; Tanuri A; Souza TML; Rossi-Bergmann B; Vale AM; Silva JL; de Oliveira AC; Filardy AD; Gomes AMO; de Matos Guedes HL
    Front Immunol; 2022; 13():884760. PubMed ID: 35844561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the immunogenicity of gold nanoparticles conjugated RBD with Freund's adjuvant as a potential vaccine against SARS-CoV-2.
    Moshref Javadi M; Taghdisi Hosseinzadeh M; Soleimani N; Rommasi F
    Microb Pathog; 2022 Sep; 170():105687. PubMed ID: 35917987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
    Liu X; Drelich A; Li W; Chen C; Sun Z; Shi M; Adams C; Mellors JW; Tseng CT; Dimitrov DS
    Vaccine; 2020 Oct; 38(46):7205-7212. PubMed ID: 33010978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants.
    Bajoria S; Kaur K; Kumru OS; Van Slyke G; Doering J; Novak H; Rodriguez Aponte SA; Dalvie NC; Naranjo CA; Johnston RS; Silverman JM; Kleanthous H; Love JC; Mantis NJ; Joshi SB; Volkin DB
    Hum Vaccin Immunother; 2022 Nov; 18(5):2079346. PubMed ID: 35666264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.